BMS-986020 ( DrugBank: BMS-986020 )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1
85	特発性間質性肺炎	1

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02588625 (ClinicalTrials.gov)	February 2016	26/10/2015	A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)	A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Scleroderma	Drug: BMS-986020;Other: Placebo	Bristol-Myers Squibb	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 2	United States;Canada;Poland;United Kingdom;France

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01766817 (ClinicalTrials.gov)	January 31, 2013	10/1/2013	Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis	Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: BMS-986020;Drug: Placebo matching with BMS-986020	Bristol-Myers Squibb	NULL	Completed	40 Years	90 Years	All	325	Phase 2	United States;Australia;Chile;Colombia;Mexico;Peru